TXG * Stock Overview
A life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
10x Genomics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$440.00 |
| 52 Week High | US$440.00 |
| 52 Week Low | US$367.32 |
| Beta | 1.87 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -87.45% |
| 5 Year Change | n/a |
| Change since IPO | -88.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| TXG * | MX Life Sciences | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how TXG * performed against the MX Life Sciences industry.
Return vs Market: Insufficient data to determine how TXG * performed against the MX Market.
Price Volatility
| TXG * volatility | |
|---|---|
| TXG * Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: TXG *'s share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine TXG *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 1,259 | Serge Saxonov | www.10xgenomics.com |
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell.
10x Genomics, Inc. Fundamentals Summary
| TXG * fundamental statistics | |
|---|---|
| Market cap | Mex$35.48b |
| Earnings (TTM) | -Mex$3.74b |
| Revenue (TTM) | Mex$12.90b |
2.8x
P/S Ratio-9.5x
P/E RatioIs TXG * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TXG * income statement (TTM) | |
|---|---|
| Revenue | US$629.74m |
| Cost of Revenue | US$210.13m |
| Gross Profit | US$419.61m |
| Other Expenses | US$602.16m |
| Earnings | -US$182.55m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.51 |
| Gross Margin | 66.63% |
| Net Profit Margin | -28.99% |
| Debt/Equity Ratio | 0% |
How did TXG * perform over the long term?
See historical performance and comparison